Stock analysts at Zacks Research issued their Q1 2027 earnings estimates for Nektar Therapeutics in a research report issued on Wednesday, April 2nd. Zacks Research analyst K. Das forecasts that the ...

Nektar Therapeutics (NASDAQ:NKTR – Get Free Report) has been assigned a consensus recommendation of “Buy” from the seven ...

Major indices turned in a mixed performance on Monday as market participants patiently awaited clarity on Donald Trump's ...

Major indices were in the red early on Monday as market participants patiently awaited clarity on Donald Trump's planned ...

The interleukin-2 (IL-2) therapies market in the USA is poised for major growth, projected to reach $4 billion by 2034, ...

Nektar Therapeutics (NASDAQ:NKTR) operates as a biopharmaceutical company that discovers and develops therapies to treat autoimmune disorders. Its products include NKTR-358, PEG-CSF1, and others. The ...

In this article, we are going to take a look at where Nektar Therapeutics (NASDAQ:NKTR) stands against other stocks that Wall Street is calling bullish amid market turmoil. The S&P 500 is down 8.6 ...

In this article, we are going to take a look at where Nektar Therapeutics (NASDAQ:NKTR) stands against other stocks that Wall Street is calling bullish amid market turmoil. The S&P 500 is down 8.6% in ...

U.S. stocks ended lower Thursday, with the S&P 500 and Nasdaq resuming the rout that landed the two indexes in correction territory recently. Somewhat optimistic comments from Federal Reserve ...